vs

Side-by-side financial comparison of PACIFIC BIOSCIENCES OF CALIFORNIA, INC. (PACB) and Quanterix Corp (QTRX). Click either name above to swap in a different company.

PACIFIC BIOSCIENCES OF CALIFORNIA, INC. is the larger business by last-quarter revenue ($44.6M vs $43.9M, roughly 1.0× Quanterix Corp). Quanterix Corp runs the higher net margin — -52.7% vs -90.4%, a 37.7% gap on every dollar of revenue. On growth, Quanterix Corp posted the faster year-over-year revenue change (24.7% vs 13.8%). Quanterix Corp produced more free cash flow last quarter ($-16.5M vs $-19.9M). Over the past eight quarters, Quanterix Corp's revenue compounded faster (16.9% CAGR vs 7.3%).

Pacific Biosciences of California, Inc. is an American biotechnology company founded in 2004 that develops and manufactures systems for gene sequencing and some novel real time biological observation. PacBio has two principal sequencing platforms: single-molecule real-time sequencing (SMRT), based on the properties of zero-mode waveguides and sequencing by binding (SBB) chemistry, which uses native nucleotides and scarless incorporation for DNA binding and extension.

Quanterix Corp is a life sciences firm that develops, manufactures, and commercializes ultra-sensitive single-molecule detection diagnostic platforms, reagents, and testing services. Its solutions empower biological research, drug development, and clinical diagnostics across oncology, neurodegenerative disorders, infectious diseases, and other therapeutic areas, serving research institutions, biopharmaceutical companies, and clinical laboratories globally.

PACB vs QTRX — Head-to-Head

Bigger by revenue
PACB
PACB
1.0× larger
PACB
$44.6M
$43.9M
QTRX
Growing faster (revenue YoY)
QTRX
QTRX
+10.9% gap
QTRX
24.7%
13.8%
PACB
Higher net margin
QTRX
QTRX
37.7% more per $
QTRX
-52.7%
-90.4%
PACB
More free cash flow
QTRX
QTRX
$3.4M more FCF
QTRX
$-16.5M
$-19.9M
PACB
Faster 2-yr revenue CAGR
QTRX
QTRX
Annualised
QTRX
16.9%
7.3%
PACB

Income Statement — Q4 2025 vs Q4 2025

Metric
PACB
PACB
QTRX
QTRX
Revenue
$44.6M
$43.9M
Net Profit
$-40.4M
$-23.1M
Gross Margin
37.1%
45.7%
Operating Margin
-92.3%
-56.4%
Net Margin
-90.4%
-52.7%
Revenue YoY
13.8%
24.7%
Net Profit YoY
-1802.7%
-98.8%
EPS (diluted)
$-0.11
$-0.48

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
PACB
PACB
QTRX
QTRX
Q4 25
$44.6M
$43.9M
Q3 25
$38.4M
$40.2M
Q2 25
$39.8M
$24.5M
Q1 25
$37.2M
$30.3M
Q4 24
$39.2M
$35.2M
Q3 24
$40.0M
$35.8M
Q2 24
$36.0M
$34.4M
Q1 24
$38.8M
$32.1M
Net Profit
PACB
PACB
QTRX
QTRX
Q4 25
$-40.4M
$-23.1M
Q3 25
$-38.0M
$-33.5M
Q2 25
$-41.9M
$-30.0M
Q1 25
$-426.1M
$-20.5M
Q4 24
$2.4M
$-11.6M
Q3 24
$-60.7M
$-8.4M
Q2 24
$-173.3M
$-7.4M
Q1 24
$-78.2M
$-11.2M
Gross Margin
PACB
PACB
QTRX
QTRX
Q4 25
37.1%
45.7%
Q3 25
41.4%
42.8%
Q2 25
36.9%
46.2%
Q1 25
-3.7%
54.1%
Q4 24
25.6%
63.0%
Q3 24
25.0%
56.3%
Q2 24
16.5%
64.7%
Q1 24
29.1%
57.8%
Operating Margin
PACB
PACB
QTRX
QTRX
Q4 25
-92.3%
-56.4%
Q3 25
-101.1%
-92.8%
Q2 25
-112.8%
-151.6%
Q1 25
-1154.5%
-86.9%
Q4 24
-390.1%
-42.0%
Q3 24
-160.3%
-32.8%
Q2 24
-488.3%
-31.8%
Q1 24
-209.6%
-47.3%
Net Margin
PACB
PACB
QTRX
QTRX
Q4 25
-90.4%
-52.7%
Q3 25
-98.9%
-83.3%
Q2 25
-105.4%
-122.6%
Q1 25
-1146.8%
-67.6%
Q4 24
6.0%
-33.1%
Q3 24
-151.9%
-23.3%
Q2 24
-481.3%
-21.5%
Q1 24
-201.4%
-34.8%
EPS (diluted)
PACB
PACB
QTRX
QTRX
Q4 25
$-0.11
$-0.48
Q3 25
$-0.13
$-0.73
Q2 25
$-0.14
$-0.77
Q1 25
$-1.44
$-0.53
Q4 24
$-0.44
$-0.30
Q3 24
$-0.22
$-0.22
Q2 24
$-0.64
$-0.19
Q1 24
$-0.29
$-0.29

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
PACB
PACB
QTRX
QTRX
Cash + ST InvestmentsLiquidity on hand
$279.5M
$29.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$5.3M
$295.7M
Total Assets
$784.1M
$418.8M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
PACB
PACB
QTRX
QTRX
Q4 25
$279.5M
$29.8M
Q3 25
$298.7M
$38.3M
Q2 25
$314.7M
$132.9M
Q1 25
$343.1M
$76.5M
Q4 24
$389.9M
$56.7M
Q3 24
$471.1M
$29.3M
Q2 24
$509.8M
$47.0M
Q1 24
$561.9M
$45.3M
Stockholders' Equity
PACB
PACB
QTRX
QTRX
Q4 25
$5.3M
$295.7M
Q3 25
$36.1M
$314.5M
Q2 25
$61.5M
$292.5M
Q1 25
$91.6M
$316.4M
Q4 24
$506.6M
$330.0M
Q3 24
$453.1M
$338.9M
Q2 24
$492.7M
$340.8M
Q1 24
$649.0M
$343.4M
Total Assets
PACB
PACB
QTRX
QTRX
Q4 25
$784.1M
$418.8M
Q3 25
$803.2M
$444.1M
Q2 25
$825.5M
$375.6M
Q1 25
$860.8M
$396.5M
Q4 24
$1.3B
$406.5M
Q3 24
$1.5B
$411.0M
Q2 24
$1.5B
$415.9M
Q1 24
$1.7B
$414.2M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
PACB
PACB
QTRX
QTRX
Operating Cash FlowLast quarter
$-19.1M
$-16.4M
Free Cash FlowOCF − Capex
$-19.9M
$-16.5M
FCF MarginFCF / Revenue
-44.6%
-37.7%
Capex IntensityCapex / Revenue
1.9%
0.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-114.1M
$-80.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
PACB
PACB
QTRX
QTRX
Q4 25
$-19.1M
$-16.4M
Q3 25
$-18.7M
$-41.2M
Q2 25
$-29.4M
$-5.7M
Q1 25
$-44.1M
$-13.9M
Q4 24
$-30.6M
$-4.3M
Q3 24
$-45.5M
$-5.7M
Q2 24
$-54.3M
$-5.0M
Q1 24
$-75.7M
$-20.2M
Free Cash Flow
PACB
PACB
QTRX
QTRX
Q4 25
$-19.9M
$-16.5M
Q3 25
$-18.8M
$-41.9M
Q2 25
$-29.9M
$-6.4M
Q1 25
$-45.4M
$-15.1M
Q4 24
$-32.3M
$-4.7M
Q3 24
$-46.3M
$-6.6M
Q2 24
$-55.7M
$-6.5M
Q1 24
$-79.6M
$-20.7M
FCF Margin
PACB
PACB
QTRX
QTRX
Q4 25
-44.6%
-37.7%
Q3 25
-48.9%
-104.2%
Q2 25
-75.3%
-26.3%
Q1 25
-122.3%
-49.9%
Q4 24
-82.3%
-13.4%
Q3 24
-115.7%
-18.4%
Q2 24
-154.8%
-19.1%
Q1 24
-205.0%
-64.5%
Capex Intensity
PACB
PACB
QTRX
QTRX
Q4 25
1.9%
0.2%
Q3 25
0.2%
1.7%
Q2 25
1.4%
3.2%
Q1 25
3.7%
4.1%
Q4 24
4.1%
1.2%
Q3 24
2.0%
2.4%
Q2 24
4.1%
4.7%
Q1 24
10.0%
1.6%
Cash Conversion
PACB
PACB
QTRX
QTRX
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
-12.93×
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

PACB
PACB

Products$39.0M87%
Service And Other$5.7M13%

QTRX
QTRX

Products$29.2M67%
Consumable And Other Products$12.7M29%
Service Type Warranties$1.7M4%

Related Comparisons